Latest Industry Insights

To learn more about NASH “in-a-box” and how it can help to advance drug discovery for NASH, Technology Networks spoke to Dr. Audrey Dubourg.

Technology Networks had the pleasure of interviewing Sunny Himansu M.B.B.S., D.SM – associate director, infectious diseases at Moderna – to discuss the biotech company's pipeline, how a collaboration with IAVI aims to make mRNA-based preventives and therapeutics globally accessible and the future of mRNA in medicine.

Technology Networks had the pleasure of speaking with Thermo Fisher Scientific’s Don Paul Kovarcik, to learn more about the benefits and limitations of electroporation and key factors affecting electroporation performance.

For the world’s leading neuroscientists, unlocking the brain’s capacity to stimulate neural plasticity has become something of a Holy Grail. In this Insight, NervGen Pharma president and CEO Paul Brennan details why plasticity is so important for the brain.

In this interview we speak to Sean Mackay, CEO of IsoPlexis, to discuss how single-cell functional proteomics have helped researchers understand the risk factors behind long COVID.

Emulate's chief scientific officer, Dr. Lorna Ewart, talks about inspiring a new generation of women in STEM.

To learn more about the world's first Microhub – Mica – and some of the areas it could impact the most, Technology Networks spoke to James O’Brien, vice president life sciences at Leica Microsystems.

In honor of International Day of Women and Girls in Science 2022, Technology Networks interviewed three women who have built successful careers within the scientific industry, to learn about their career paths and the reasons they chose to work in industry.

Technology Networks spoke with Michael Yang, president and chief executive officer of ViaCyte, to learn more about the development of a stem cell-derived therapy for the treatment of T1D and the technology behind it.

With a reliance on single-use plastics, significant waste and high energy usage, the carbon footprint of the biopharma industry is large. If we are to accelerate the path to net zero, it is therefore critical to ensure sustainability in science.